Phase 2 Clinical Study of CYT-108 for Osteoarthritis patients
Latest Information Update: 26 Mar 2025
At a glance
- Drugs CYT 108 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- 26 Mar 2025 New trial record
- 25 Mar 2025 According to a Cytonics Corporation media release, the company seeks $24 million to pursue FDA phase 2 clinical study of CYT-108, the company's novel therapy for osteoarthritis